EC Number   |
Application |
Reference |
|---|
   2.7.11.31 | drug development |
activating AMPK may have therapeutic potential in treating dry macular degeneration |
704459 |
| 2.7.11.31 | drug development |
AMP-activated protein kinase (AMPK) is a potential target for drug design against metabolic syndrome, obesity and type 2 diabetes |
739785 |
| 2.7.11.31 | drug development |
AMPK alpha2beta2gamma3 is an attractive target for drug development for diabetes and metabolic syndrome |
741365 |
| 2.7.11.31 | drug development |
AMPK is a highly attractive target for the prevention and treatment of type 2 diabetes and other disorders of the metabolic syndrome, and to curb the prevalence and costs of type 2 diabetes |
701571 |
| 2.7.11.31 | drug development |
AMPK is regarded as one of the most promising targets for new drugs to treat the growing incidence of metabolic diseases such as obesity and type 2 diabetes and cardiovascular disease |
701572 |
| 2.7.11.31 | drug development |
AMPK represents an attractive therapeutic target for vascular disease treatment |
703348 |
| 2.7.11.31 | drug development |
design and development of isoform-selective AMPK activators that are likely to be useful for the treatment of cardiovascular and metabolic diseases |
740018 |
| 2.7.11.31 | drug development |
pharmacological activators of AMPK can act as treatments for diabetes and the metabolic syndrome |
692365 |
| 2.7.11.31 | drug development |
targeting SIRT1-AMPK pathway may serve as a new target for the development of new anti HIV-1 agents |
706902 |
| 2.7.11.31 | drug development |
the AMPK inhibitor 6-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-3-pyridin-4-yl-pyrrazolo[1,5-a]-pyrimidine may serve as a useful molecule in both basic and clinical research on adipogenesis and as a potential lead compound for the treatment of obesity |
702510 |
